| solute carrier family 5 member 2 | OKDB#: 5562 |
| Symbols: | SLC5A2 | Species: | human | ||
| Synonyms: | SGLT2 | Locus: | 16p11.2 in Homo sapiens |
|
For retrieval of Nucleotide and Amino Acid sequences please go to:
OMIM
Entrez Gene
Mammalian Reproductive Genetics Endometrium Database Resource Orthologous Genes UCSC Genome Browser GEO Profiles new! Amazonia (transcriptome data) new! R-L INTERACTIONS MGI |
| General Comment |
SGLT2 inhibitors help the kidneys lower blood glucose levels
SGLT2 inhibitors help the kidneys lower blood glucose levels
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new group of oral medications used for treating type 2 diabetes. The drugs work by helping the kidneys to lower blood glucose levels.
SGLT2 inhibitors have been approved for use as a treatment for diabetes since 2013. They are taken once a day with or without food.
The following drugs belong to the SGLT2 inhibitors class (trade name first, generic name in brackets):
Forxiga (Dapagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
NCBI Summary: This gene encodes a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. The encoded protein is the major cotransporter involved in glucose reabsorption in the kidney. Mutations in this gene are associated with renal glucosuria. Two transcript variants, one protein-coding and one not, have been found for this gene. [provided by RefSeq, Feb 2015] |
||||
| General function | Channel/transport protein | ||||
| Comment | |||||
| Cellular localization | Plasma membrane | ||||
| Comment | |||||
| Ovarian function | |||||
| Comment | Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. Marinkovic-Radosevic J et al. (2021) Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences. A plethora of symptoms and their severity differentiate on an individual level, giving the syndrome numerous phenotypes. Due to menstrual cycle abnormalities, women suffer from irregular menstrual bleeding, difficulty in conception, and infertility. Furthermore, the risk of pregnancy complications such as gestational diabetes mellitus, hypertensive disorders of pregnancy, and preterm birth are higher in women with PCOS than in the general population. Often, women with PCOS have comorbidities such as dyslipidemia, obesity, glucose intolerance or diabetes type 2, non-alcoholic fatty liver disease, and metabolic syndrome, which all influence the treatment plan. Historic insulin-sensitizing agents, although good for some of the metabolic derangements, do not offer long-term cardiovascular benefits; therefore, new treatment options are of paramount importance. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, a new class of antidiabetic agents with beneficial cardiovascular, bodyweight, and antihyperglycemic effects, although not approved for the treatment of PCOS, might be an attractive therapeutic addition in the PCOS armamentarium. Namely, recent studies with SGLT-2 inhibitors showed promising improvements in anthropometric parameters and body composition in patients with PCOS. It is important to further explore the SGLT-2 inhibitors potential as an early therapeutic option because of the PCOS-related risk of metabolic, reproductive, and psychological consequences.////////////////// | ||||
| Expression regulated by | |||||
| Comment | |||||
| Ovarian localization | Granulosa | ||||
| Comment | |||||
| Follicle stages | |||||
| Comment | |||||
| Phenotypes |
PCO (polycystic ovarian syndrome) |
||||
| Mutations | 0 mutations | ||||
| Genomic Region | show genomic region | ||||
| Phenotypes and GWAS | show phenotypes and GWAS | ||||
| Links |
|
| created: | June 25, 2018, 11:57 a.m. | by: |
system email:
home page: |
| last update: | Aug. 4, 2021, 1:34 p.m. | by: | hsueh email: |
Click here to return to gene search form